Skip to content

12 Dec 2022

EpiEndo Pharmaceuticals to attend SCIENCE4PEACE

SCIENCE4PEACE is a unique manifestation of the Swedish - American Life Science Summit (SALSS) together with The Galien Foundation, taking place in Stockholm, Sweden on the 12th of December during the Nobel festivities.

On December 12th, 2022, some of the most distinguished scientists in the world, political leaders and life science executives will gather in Stockholm to talk about the future of healthcare and inspire each other to take action in maintaining science diplomacy.

Perhaps now more than ever, strong global relationships are essential in addressing international challenges. Scientists can be powerful bridge builders, even opening doors between countries that might otherwise remain closed.” Barbro C. Ehnbom, Founder and Chairman of SALSS.

The focus of SALSS this year is Future of Healthcare with speakers specializing in the fields of Precision Medicine and Biotechnology Convergence. Moreover, SALSS will include thought-provoking panel debates on topics such as Tomorrow’s Healthcare, as well as diving deeper into the future of Precision Medicine, and highlighting the need for peace in the scientific community.

Gathering an impressive presence of Nobel Laureates, Academics, Government Officials, Investors, Life Science Executives and Entrepreneurs this year's program features among others Emmanuelle Charpentier, Scientific & Managing Director, Max Planck Unit for the Science of Pathogens, Nobel laureate, Mathias Uhlén, Professor KTH, Dr. William A. Haseltine, President, Access Health International,Thomas Sakmar, Professor Rockefeller University, and Dr. Tim Opler Partner & Co-Founder, Torreya Partners, Chairman of Emerald Bioventures. Presenting companies this year include Akthelia, BioArctic, CELLINK, Devyser, EpiEndo and LIDDS Pharma. CEOs of the companies will showcase their exciting breakthroughs and form new business relationships with investors and other partners.

The future of healthcare is incredibly exciting as current trends will lead to broad social applications of biological breakthroughs, such as gene editing and bioelectronics. Further, new emerging integrated business models will allow key sectors, including pharmaceuticals, to experience unprecedented value accretion in the decades ahead.” Dr. Tim Opler, Partner & Co-Founder, Torreya Partners, and Chairman of Emerald Bioventures.

For more information on SALSS, please visit and or reach out to us:

Irina Polishchuk +358 468 121 629

Barbro Ehnbom +46 (0) 705 938 335